Today’s closing price bodes well for next month. I was hoping the stock will recover to $2 this month and $1.985 is close enough.

Here’s a list of potential catalysts in September:
- Completion of Kevetrin (Phase 1)
- Start of K-AML (Phase 2)
- Trial Design on B-ABSSSI (Phase 3)
- Enrollment Status of B-OM & Prurisol (Phase 2)
- 10-K / Nasdaq Uplist
- Corporate Update